Advances in the understanding, management, and prevention of dengue

Journal of Clinical Virology

Volumn 64, Issue , 2015, Pages 153-159

  Hermann, Laura L ^a,b   Gupta, Swati B ^c   Manoff, Susan B ^c   Kalayanarooj, Siripen ^d   Gibbons, Robert V ^b   Coller, Beth Ann G ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c MERCK RESEARCH LABORATORIES   (United States)

^d QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

Author keywords

Dengue; Diagnosis; Epidemiology; Treatment; Vaccine

Indexed keywords

ANTIVIRUS AGENT; DENGUE VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DENGUE; DEVELOPING COUNTRY; DIAGNOSTIC TEST; DISEASE EXACERBATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EPIDEMIOLOGY; HEALTH CARE PLANNING; HUMAN; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOLOGY; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; NONHUMAN; PATIENT CARE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAPID DIAGNOSTIC TEST; SEROLOGY; VECTOR CONTROL; VIROLOGY; VIRUS DETECTION; ANIMAL; DISEASE MANAGEMENT;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VACCINES; DISEASE MANAGEMENT; HUMANS;

EID: 84923369779     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.08.031     Document Type: Article

References (138)

1. Brady O.J., Gething P.W., Bhatt S., Messina J.P., Brownstein J.S., Hoen A.G., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012, 6(8):e1760.
2. Gubler D.J. Emerging vector-borne flavivirus diseases: are vaccines the solution?. Expert Rev Vaccines 2011, 10(5):563-565.
3. World Health Organization The world health report 2003 - annex table 3: burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002 2004, The World Health Report, Geneva, Switzerland, Ref Type: Report.
4. Guzman M.G., Kouri G. Dengue in Cuba: research strategy to support dengue control. Lancet 2009, 374(9702):1660-1661.
5. Simmons C.P., Farrar J.J., van Vinh C.N., Wills B. Dengue. N Engl J Med 2012, 366(15):1423-1432.
6. Tapia-Conyer R., Mendez-Galvan J.F., Gallardo-Rincon H. The growing burden of dengue in Latin America. J Clin Virol 2009, 46(Suppl. 2):S3-S6.
7. World Health Organization Dengue haemorrhagic fever: diagnosis, treatment, prevention and control 1997, Global Alert Response, Geneva. 2nd ed.
8. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(7446):504-507.
9. Endy T.P., Chunsuttiwat S., Nisalak A., Libraty D.H., Green S., Rothman A.L., et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002, 156(1):40-51.
10. Cummings D.A., Iamsirithaworn S., Lessler J.T., McDermott A., Prasanthong R., Nisalak A., et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med 2009, 6(9):e1000139.
11. Lee K.S., Lai Y.L., Lo S., Barkham T., Aw P., Ooi P.L., et al. Dengue virus surveillance for early warning, Singapore. Emerg Infect Dis 2010, 16(5):847-849.
12. San Martin J.L., Brathwaite O., Zambrano B., Solorzano J.O., Bouckenooghe A., Dayan G.H., et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 2010, 82(1):128-135.
13. World Health Organization Dengue: guidelines for diagnosis, treatment, prevention and control: new edition 2009, World Health Organization, France, Ref Type: Report.
14. Lambrechts L., Fansiri T., Pongsiri A., Thaisomboonsuk B., Klungthong C., Richardson J.H., et al. Dengue-1 virus clade replacement in Thailand associated with enhanced mosquito transmission. J Virol 2012, 86(3):1853-1861.
15. Siqueira J.B., Folador da Fonseca G., Rocha Simplicio A.C., Vinhal L.C., Coelho G.E. Morbidity and mortality of dengue in Brazil: a decade in perspective. Brazil health 2009: an analysis of the health situation and the national and international health priority agenda 2011, 241-256. Ministry of Health, Brasilia. 1st ed. - 2010 ed.
16. Were F. The dengue situation in Africa. Paediatr Int Child Health 2012, 32(Suppl. 1):18-21.
17. Amarasinghe A., Kuritsk J.N., Letson G.W., Margolis H.S. Dengue virus infection in Africa. Emerg Infect Dis 2011, 17(8):1349-1354.
18. Franco L., Di Caro A., Carletti F., Vapalahti O., Renaudat C., Zeller H., et al. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill 2010, 15(7).
19. Adalja A.A., Sell T.K., Bouri N., Franco C. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerg Infect Dis 2012, 18(4):608-614.
20. La Ruche G., Souares Y., Armengaud A., Peloux-Petiot F., Delaunay P., Despres P., et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill 2010, 15(39):19676.
21. Schmidt-Chanasit J., Haditsch M., Schoneberg I., Gunther S., Stark K., Frank C. Dengue virus infection in a traveller returning from Croatia to Germany. Euro Surveill 2010, 15(40).
22. Sousa C.A., Clairouin M., Seixas G., Viveiros B., Novo M.T., Silva A.C., et al. Ongoing outbreak of dengue type 1 in the Autonomous Region of Madeira, Portugal: preliminary report. Euro Surveill 2012, 17(49).
23. Kyle J.L., Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008, 62:71-92.
24. Scott T.W., Morrison A.C. Vector dynamics and transmission of dengue virus: implications for dengue surveillance and prevention strategies: vector dynamics and dengue prevention. Curr Top Microbiol Immunol 2010, 338:115-128.
25. Lowe R., Bailey T.C., Stephenson D.B., Jupp T.E., Graham R.J., Barcellos C., et al. The development of an early warning system for climate-sensitive disease risk with a focus on dengue epidemics in Southeast Brazil. Stat Med 2013, 32(5):864-883.
26. Dengue - an infectious disease of staggering, proportions. Lancet 2013, 381(9884):2136.
27. Chakravarti A., Kumaria R. Eco-epidemiological analysis of dengue infection during an outbreak of dengue fever, India. Virol J 2005, 2:32.
28. Barclay E. Is climate change affecting dengue in the Americas. Lancet 2008, 371(9617):973-974.
29. Tjaden N.B., Thomas S.M., Fischer D., Beierkuhnlein C. Extrinsic incubation period of dengue: knowledge, backlog, and applications of temperature dependence. PLoS Negl Trop Dis 2013, 7(6):e2207.
30. Stoddard S.T., Forshey B.M., Morrison A.C., Paz-Soldan V.A., Vazquez-Prokopec G.M., Astete H., et al. House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci USA 2013, 110(3):994-999.
31. Salje H., Lessler J., Endy T.P., Curriero F.C., Gibbons R.V., Nisalak A., et al. Revealing the microscale spatial signature of dengue transmission and immunity in an urban population. Proc Natl Acad Sci USA 2012, 109(24):9535-9538.
32. Liebman K.A., Stoddard S.T., Morrison A.C., Rocha C., Minnick S., Sihuincha M., et al. Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003). PLoS Negl Trop Dis 2012, 6(2):e1472.
33. Beatty M.E., Stone A., Fitzsimons D.W., Hanna J.N., Lam S.K., Vong S., et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis 2010, 4(11):e890.
34. Tun-Lin W., Lenhart A., Nam V.S., Rebollar-Tellez E., Morrison A.C., Barbazan P., et al. Reducing costs and operational constraints of dengue vector control by targeting productive breeding places: a multi-country non-inferiority cluster randomized trial. Trop Med Int Health 2009, 14(9):1143-1153.
35. Lorono-Pino M.A., Garcia-Rejon J.E., Machain-Williams C., Gomez-Carro S., Nunez-Ayala G., Najera-Vazquez M.R., et al. Towards a Casa Segura: a consumer product study of the effect of insecticide-treated curtains on Aedes aegypti and dengue virus infections in the home. Am J Trop Med Hyg 2013, 89(2):385-397.
36. Lenhart A., Orelus N., Maskill R., Alexander N., Streit T., McCall P.J. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 2008, 13(1):56-67.
37. Kroeger A., Lenhart A., Ochoa M., Villegas E., Levy M., Alexander N., et al. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomised trials. Br Med J 2006, 332(7552):1247-1252.
38. Esu E., Lenhart A., Smith L., Horstick O. Effectiveness of peridomestic space spraying with insecticide on dengue transmission; systematic review. Trop Med Int Health 2010, 15(5):619-631.
39. Seng C.M., Setha T., Nealon J., Socheat D., Chantha N., Nathan M.B. Community-based use of the larvivorous fish Poecilia reticulata to control the dengue vector Aedes aegypti in domestic water storage containers in rural Cambodia. J Vector Ecol 2008, 33(1):139-144.
40. McGraw E.A., O'Neill S.L. Beyond insecticides: new thinking on an ancient problem. Nat Rev Microbiol 2013, 11(3):181-193.
41. McMeniman C.J., Lane R.V., Cass B.N., Fong A.W., Sidhu M., Wang Y.F., et al. Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti. Science 2009, 323(5910):141-144.
42. Bian G., Xu Y., Lu P., Xie Y., Xi Z. The endosymbiotic bacterium Wolbachia induces resistance to dengue virus in Aedes aegypti. PLoS Pathog 2010, 6(4):e1000833.
43. Turley A.P., Moreira L.A., O'Neill S.L., McGraw E.A. Wolbachia infection reduces blood-feeding success in the dengue fever mosquito, Aedes aegypti. PLoS Negl Trop Dis 2009, 3(9):e516.
44. Iturbe-Ormaetxe I., Walker T., O'Neill S.L. Wolbachia and the biological control of mosquito-borne disease. EMBO Rep 2011, 12(6):508-518.
45. Walker T., Johnson P.H., Moreira L.A., Iturbe-Ormaetxe I., Frentiu F.D., McMeniman C.J., et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 2011, 476(7361):450-453.
46. Hoffmann A.A., Montgomery B.L., Popovici J., Iturbe-Ormaetxe I., Johnson P.H., Muzzi F., et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 2011, 476(7361):454-457.
47. Darbro J.M., Johnson P.H., Thomas M.B., Ritchie S.A., Kay B.H., Ryan P.A. Effects of Beauveria bassiana on survival, blood-feeding success, and fecundity of Aedes aegypti in laboratory and semi-field conditions. Am J Trop Med Hyg 2012, 86(4):656-664.
48. Lacroix R., McKemey A.R., Raduan N., Kwee W.L., Hong M.W., Guat N.T., et al. Open field release of genetically engineered sterile male Aedes aegypti in Malaysia. PLoS ONE 2012, 7(8):e42771.
49. Schraiber J.G., Kaczmarczyk A.N., Kwok R., Park M., Silverstein R., Rutaganira F.U., et al. Constraints on the use of lifespan-shortening Wolbachia to control dengue fever. J Theor Biol 2012, 297:26-32.
50. Anders K.L., Hay S.I. Lessons from malaria control to help meet the rising challenge of dengue. Lancet Infect Dis 2012, 12(12):977-984.
51. Luz P.M., Vanni T., Medlock J., Paltiel A.D., Galvani A.P. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet 2011, 377(9778):1673-1680.
52. Guzman M.G., Alvarez M., Halstead S.B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 2013, 158(7):1445-1459.
53. Simmons C.P., Dong T., Chau N.V., Dung N.T., Chau T.N., Thao lT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005, 79(9):5665-5675.
54. Beaumier C.M., Jaiswal S., West K.Y., Friberg H., Mathew A., Rothman A.L. Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells. Viral Immunol 2010, 23(5):477-485.
55. Duangchinda T., Dejnirattisai W., Vasanawathana S., Limpitikul W., Tangthawornchaikul N., Malasit P., et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010, 107(39):16922-16927.
56. Espada-Murao L.A., Morita K. Dengue and soluble mediators of the innate immune system. Trop Med Health 2011, 39(Suppl. 4):53-62.
57. Halstead S.B. Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009, 1171(Suppl. 1):E48-E56.
58. Wrammert J., Onlamoon N., Akondy R.S., Perng G.C., Polsrila K., Chandele A., et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 2012, 86(6):2911-2918.
59. Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012, 188(1):404-416.
60. Costin J.M., Zaitseva E., Kahle K.M., Nicholson C.O., Rowe D.K., Graham A.S., et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 2013, 87(1):52-66.
61. Schieffelin J.S., Costin J.M., Nicholson C.O., Orgeron N.M., Fontaine K.A., Isern S., et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 2010, 7:28.
62. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8(3):271-283.
63. Wahala W.M., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392(1):103-113.
64. de Alwis R., Beltramello M., Messer W.B., Sukupolvi-Petty S., Wahala W.M., Kraus A., et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011, 5(6):e1188.
65. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013, 110(22):E2046-E2053.
66. Smith S.A., Zhou Y., Olivarez N.P., Broadwater A.H., de Silva A.M., Crowe J.E. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 2012, 86(5):2665-2675.
67. Lai C.Y., Tsai W.Y., Lin S.R., Kao C.L., Hu H.P., King C.C., et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008, 82(13):6631-6643.
68. Williams K.L., Wahala W.M., Orozco S., de Silva A.M., Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012, 429(1):12-20.
69. Chau T.N., Quyen N.T., Thuy T.T., Tuan N.M., Hoang D.M., Dung N.T., et al. Dengue in Vietnamese infants - results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 2008, 198(4):516-524.
70. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012, 109:7439-7444.
71. Sukupolvi-Petty S., Austin S.K., Engle M., Brien J.D., Dowd K.A., Williams K.L., et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010, 84(18):9227-9239.
72. Avirutnan P., Mehlhop E., Diamond M.S. Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 2008, 26(Suppl. 8):I100-I107.
73. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007, 2(6):417-426.
74. Avirutnan P., Fuchs A., Hauhart R.E., Somnuke P., Youn S., Diamond M.S., et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010, 207(4):793-806.
75. Dunn M.D., Rossi S.L., Carter D.M., Vogt M.R., Mehlhop E., Diamond M.S., et al. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J 2010, 7:95.
76. Vogt M.R., Dowd K.A., Engle M., Tesh R.B., Johnson S., Pierson T.C., et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 2011, 85(22):11567-11580.
77. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
78. Rodenhuis-Zybert I.A., van der Schaar H.M., Silva Voorham J.M., Ende-Metselaar H., Lei H.Y., Wilschut J., et al. Immature dengue virus: a veiled pathogen?. PLoS Pathog 2010, 6(1):e1000718.
79. Rodenhuis-Zybert I.A., Wilschut J., Smit J.M. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci 2010, 67(16):2773-2786.
80. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008, 15(3):312-317.
81. Cherrier M.V., Kaufmann B., Nybakken G.E., Lok S.M., Warren J.T., Chen B.R., et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 2009, 28(20):3269-3276.
82. Midgley C.M., Flanagan A., Tran H.B., Dejnirattisai W., Chawansuntati K., Jumnainsong A., et al. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol 2012, 188(10):4971-4979.
83. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008, 10:e12.
84. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011, 11(8):532-543.
85. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 1999, 73(1):783-786.
86. Tan G.K., Ng J.K., Trasti S.L., Schul W., Yip G., Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010, 4(4):e672.
87. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006, 80(20):10208-10217.
88. World Health Organization Comprehensive guideline for prevention and control of dengue and dengue haemorrhagic fever 2011, World Health Organization, Southeast Asia, Ref Type: Report.
89. Narvaez F., Gutierrez G., Perez M.A., Elizondo D., Nunez A., Balmaseda A., et al. Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis 2011, 5(11):e1397.
90. Kalayanarooj S. Dengue classification: current WHO vs. the newly suggested classification for better clinical application?. J Med Assoc Thai 2011, 94(Suppl. 3):S74-S84.
91. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181(1):2-9.
92. Koraka P., Suharti C., Setiati T.E., Mairuhu A.T., Van Gorp E., Hack C.E., et al. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol 2001, 39(12):4332-4338.
93. Prince H.E., Matud J.L. Estimation of dengue virus IgM persistence using regression analysis. Clin Vaccine Immunol 2011, 18(12):2183-2185.
94. Blacksell S.D., Jarman R.G., Bailey M.S., Tanganuchitcharnchai A., Jenjaroen K., Gibbons R.V., et al. Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy. Clin Vaccine Immunol 2011, 18(12):2095-2101.
95. Sa-Ngasang A., Anantapreecha S., Nuegoonpipat A., Chanama S., Wibulwattanakij S., Pattanakul K., et al. Specific IgM and IgG responses in primary and secondary dengue virus infections determined by enzyme-linked immunosorbent assay. Epidemiol Infect 2006, 134(4):820-825.
96. Blacksell S.D. Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs?. J Biomed Biotechnol 2012, 2012:151967.
97. Vaughn D.W., Nisalak A., Kalayanarooj S., Solomon T., Dung N.M., Cuzzubbo A., et al. Evaluation of a rapid immunochromatographic test for diagnosis of dengue virus infection. J Clin Microbiol 1998, 36(1):234-238.
98. Peeling R.W., Smith P.G., Bossuyt P.M. A guide for diagnostic evaluations. Nat Rev Microbiol 2010, 8(Suppl. 12):S2-S6.
99. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
100. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccine 2010, 6(9).
101. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241.
102. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
103. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29(42):7251-7260.
104. Huang C.Y., Kinney R.M., Livengood J.A., Bolling B., Arguello J.J., Luy B.E., et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013, 7(5):e2243.
105. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29(42):7242-7250.
106. Durbin A.P., Whitehead S.S., McArthur J., Perreault J.R., Blaney J.E., Thumar B., et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005, 191(5):710-718.
107. Durbin A.P., McArthur J., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccine 2006, 2(4):167-173.
108. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccine 2006, 2(6):255-260.
109. McArthur J.H., Durbin A.P., Marron J.A., Wanionek K.A., Thumar B., Pierro D.J., et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008, 79(5):678-684.
110. Wright P.F., Durbin A.P., Whitehead S.S., Ikizler M.R., Henderson S., Blaney J.E., et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 2009, 81(5):834-841.
111. Lindow J.C., Durbin A.P., Whitehead S.S., Pierce K.K., Carmolli M.P., Kirkpatrick B.D. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 2013, 31(33):3347-3352.
112. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013, 207(6):957-965.
113. Robert P.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(35):4442-4452.
114. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(15):2705-2715.
115. Coller B. Introduction: the development of dengue vaccines. Vaccine 2011, 29(42):7219-7220.
116. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29(42):7267-7275.
117. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29(5):960-968.
118. Danko J.R., Beckett C.G., Porter K.R. Development of dengue DNA vaccines. Vaccine 2011, 29(42):7261-7266.
119. Mahalingam S., Herring B.L., Halstead S.B. Call to action for dengue vaccine failure. Emerg Infect Dis 2013, 19(8):1335-1337.
120. Sun P., Kochel T.J. The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. Sci World J 2013, 2013:843469.
121. Gunther V.J., Putnak R., Eckels K.H., Mammen M.P., Scherer J.M., Lyons A., et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011, 29(22):3895-3904.
122. Statler J., Mammen M., Lyons A., Sun W. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008, 36(7):413-417.
123. Thomas S.J., Endy T.P. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24(5):442-450.
124. Thomas S.J. The necessity and quandaries of dengue vaccine development. J Infect Dis 2011, 203(3):299-303.
125. Durbin A.P., Schmidt A., Elwood D., Wanionek K.A., Lovchik J., Thumar B., et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 2011, 203(3):327-334.
126. Tomlinson S.M., Malmstrom R.D., Watowich S.J. New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets 2009, 9(3):327-343.
127. Herrero L.J., Zakhary A., Gahan M.E., Nelson M.A., Herring B.L., Hapel A.J., et al. Dengue virus therapeutic intervention strategies based on viral, vector and host factors involved in disease pathogenesis. Pharmacol Ther 2013, 137(2):266-282.
128. Luzhkov V.B., Selisko B., Nordqvist A., Peyrane F., Decroly E., Alvarez K., et al. Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2'O)-methyltransferase. Bioorg Med Chem 2007, 15(24):7795-7802.
129. Schul W., Liu W., Xu H.Y., Flamand M., Vasudevan S.G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007, 195(5):665-674.
130. Ajariyakhajorn C., Mammen M.P., Endy T.P., Gettayacamin M., Nisalak A., Nimmannitya S., et al. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. Antimicrob Agents Chemother 2005, 49(11):4508-4514.
131. Dimaano E.M., Saito M., Honda S., Miranda E.A., Alonzo M.T., Valerio M.D., et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007, 77(6):1135-1138.
132. Kharya G., Yadav S.P., Katewa S., Sachdeva A. Management of severe refractory thrombocytopenia in dengue hemorrhagic fever with intravenous anti-D immune globulin. Pediatr Hematol Oncol 2011, 28(8):727-732.
133. Tricou V., Minh N.N., Van T.P., Lee S.J., Farrar J., Wills B., et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010, 4(8):e785.
134. Nguyen N.M., Tran C.N., Phung L.K., Duong K.T., Huynh H.A., Farrar J., et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013, 207(9):1442-1450.
135. Salgado D., Zabaleta T.E., Hatch S., Vega M.R., Rodriguez J. Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. Pediatr Infect Dis J 2012, 31(7):771-773.
136. Tam D.T., Ngoc T.V., Tien N.T., Kieu N.T., Thuy T.T., Thanh L.T., et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012, 55(9):1216-1224.
137. Panpanich R., Sornchai P., Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006, (3). CD003488.
138. Whitehorn J., van Vinh C.N., Truong N.T., Tai L.T., Van Hao N., Hien T.T., et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 2012, 13:203.